Nektar Therapeutics

NASDAQ: NKTR
$10.90
-$0.28 (-2.5%)
Closing price January 25, 2022
The top analyst upgrades, downgrades and initiations seen on Thursday included Arena Pharmaceuticals, Autodesk, Coca-Cola, General Electric, Marvell, Monster Beverages, Nabors and Procter &...
Monday was a down day for the broad U.S. markets. Each of the major exchanges started out the week on a negative note, with each seeing a loss of at least 2.0%. Crude oil continued lower yet again,...
Tuesday was a positive day for the broad U.S. markets. Although there seemed to be a lot of uncertainty leading up to this Election Day, it seems the markets are taking it in stride now that it’s...
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
Monday was a mixed day for the broad U.S. markets. While all three major indices started out on a positive note, only two of the three finished there. Crude oil started out the week with a bang...
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results...
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
These four red-hot Jefferies growth stock picks could have substantial upside, especially if the market simmers down some.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altice USA, CVS Health, Exxon, Lowe's, T-Mobile, Sprint and Under Armour.
The top analyst upgrades, downgrades and other research calls from Monday include BlackBerry, BP, Camping World, Deere, GrubHub, KLA-Tencor, Teva Pharmaceutical and Zions Bancorp.
The top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, Amazon.com, AngloGold Ashanti, Bank of America, General Electric, Walt Disney and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Carnival, Facebook, Freeport-McMoRan, Motorola Solutions and Procter & Gamble.
Esperion Therapeutics and a few other biopharma stocks made massive runs on Monday morning.